Home Synthesis, characterization and bioactivity of novel 5,6-dihydropyrrolo[3,4-c]pyrazol-4- (1H)one derivatives
Article Open Access

Synthesis, characterization and bioactivity of novel 5,6-dihydropyrrolo[3,4-c]pyrazol-4- (1H)one derivatives

  • Xian-Feng Wang , Min Chen , Li-Zhi Zhang , Zheng Zhao and Chun-Long Yang EMAIL logo
Published/Copyright: November 28, 2015

Abstract

A series of novel 6-(sec-butyl)-3-methyl-1-(substituted phenyl)-5,6- dihydropyrrolo[3,4-c]pyrazol-4-(1H)ones 5a–h were synthesized using L-isoleucine methyl ester hydrochloride as the starting material. Their structures were characterized by 1H NMR, FT-IR, EI-MS and elemental analysis. Compound 5f was further analyzed by single-crystal X-ray diffraction. The bioassay results indicate that most of the compounds exhibit inhibitory activity against four plant pathogenic fungi Fusarium graminearum, Botrytis cinerea, Rhizoctonia cerealis and Colletotrichumcapsici.

Introduction

Some pyrrolopyrazole ketones containing a biheterocyclic ring system are bioactive [1–4]. The substituted 4,6-dihydropyrrolo[4,3-c]pyrazol-4-ones are useful herbicides, fungicides, insecticides or intermediate products in synthetic organic chemistry [5]. The hexahydropyrrolo[3,4-c]pyrazol-6-one derivatives can be effectively applied to plants or soils for plant disease control [6]. Another series of compounds, 4,5-dihydropyrrolo[3,4-c]pyrazol-6-(2H)ones, display activity as melanin concentrating hormone receptor-1 antagonists [7].

Tenuazonic acid [5-sec-butyl-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione, TeA, 3 in Scheme 1] is a naturally occurring tetramic acid with a broad spectrum of bioactivity [8–11]. It has been used as a lead compound to design and synthesize new bioactivitive derivatives [12–14]. In this work, the total synthesis of TeA is described for the first step. And then this compound was used to synthesize a series of substituted 4,6-dihydropyrrolo[3,4-c]pyrazol-4-(1H)ones 5a–h. Their structures were characterized by 1H NMR, FT-IR, EI-MS and elemental analysis. A single crystal X-ray diffraction analysis was conducted for the selected compound 5f. The fungicidal activity of the synthesized compounds were also evaluated.

Scheme 1 Synthetic route to title compounds 5a–h.
Scheme 1

Synthetic route to title compounds 5a–h.

Results and discussion

Tenuazonic acid 3 was prepared by intramolecular Lacey-Dieckmann condensation [15, 16] of the β-keto amide 2 which, in turn, was obtained from L-isoleucine methyl ester hydrochloride 1 as the starting material according to the reported method [17, 18].

The treatment of TeA (3) with hydrazine gave compound 4a which underwent cyclization to diastereomers 5a under acidic conditions (Scheme 1). In a similar way, the treatment of 3 with phenylhydrazine and its substituted analogs furnished the corresponding compounds 4b–h that underwent cyclization to diastereomeric products 5a–h upon treatment with acid. The yields of 5a–h ranged from 53% to 78%.

The structures of the final products 5a–h were confirmed by spectroscopic techniques and elemental analysis. Compound 5f was additionaly characterized by single crystal X-ray analysis (Table 1). The crystal structure is shown in Figure 1, and selected bond lengths and bond angles are listed in Table 2. The crystallographic analysis reveals the presence of the S,S-isomer (molecule A) and R,S-isomer (molecule B) in the asymmetric unit. They are connected by intermolecular hydrogen bonds N1-H1A···O1a and N1a-H1aA···O1 to form a stable dimer. This result confirms tautomerism in compounds 5a–h. The bond length of C11-N3 (1.422(4) Å) is shorter than the normal length of C-N single bond (1.49 Å), suggesting the presence of an electron density delocalization between two aromatic rings of benzene and pyrazole to form a large conjugated system. There is a π···π stacking interaction between the parallel benzene rings (Figure 2). The centroid to centroid distance is 4.0625 Å, and vertical distance is 3.6035 Å. The angle between the centroid to centroid line and benzene plane is 27.541°. The intermolecular hydrogen bonds and π···π stacking interactions make the crystal packings form a 3-D supramolecular structure.

Table 1

Crystallographic data for compound 5f.

Empirical formulaC16H18ClN3O
Formula weight303.79
Crystal systemTriclinic
Space groupP
a (Å)6.333(3)
b (Å)9.280(5)
c (Å)13.707(7)
α (°)94.522(6)
β (°)97.138(6)
γ (°)93.299(6)
Volume (Å3)795.0(7)
Z2
Calculated density (g⋅cm-3)1.269
Absorption coefficient (mm-1)0.243
F(000)320
Crystal size (mm3)0.30×0.26×0.20
θ range for data collection (°)2.21–26.24
Index ranges-7≤h≤7, -11≤k≤11, -17≤l≤16
Reflections collected/unique6313/3146 [R(int)=0.0453]
Completeness to θ0.983 (θ =26.24°)
Data/restraints/parameters3146/4/223
Goodness-of-fit on F20.998
Final R indices [I>2σ(I)]R1=0.0707, wR2=0.1648
R indices (all data)R1=0.0792, wR2=0.1696
Largest diff. Peak and hole (e⋅Å-3)0.280 and -0.339
Figure 1 Molecular structure of compound 5f with thermal ellipsoids drawn at the 50% probability level.Dashed lines show intramolecular hydrogen bonds.
Figure 1

Molecular structure of compound 5f with thermal ellipsoids drawn at the 50% probability level.

Dashed lines show intramolecular hydrogen bonds.

Table 2

Selected bond lengths (Å) and bond angles (°) of compound 5f.

O1-C11.227(4)N2-N31.390(4)
N1-C51.464(4)N2-C31.324(4)
N1-C11.358(4)N3-C41.352(4)
C1-C21.472(4)N3-C111.422(4)
C2-C31.414(4)Cl1-C141.745(3)
C1-N1-C5116.0(2)N2-C3-C2109.5(3)
N1-C1-C2104.9(2)N3-N2-C3106.5(2)
O1-C1-C2129.3(3)N2-N3-C4109.7(2)
O1-C1-N1125.9(3)N3-C4-C2107.8(2)
C1-C2-C3144.9(3)N3-C4-C5140.1(3)
C1-C2-C4108.5(3)C2-C4-C5112.1(2)
C3-C2-C4106.5(2)N1-C5-C498.5(2)
Figure 2 Packing diagram of compound 5f.Dashed lines show intermolecular hydrogenbonds and π···π interaction.
Figure 2

Packing diagram of compound 5f.

Dashed lines show intermolecular hydrogenbonds and π···π interaction.

Biological evaluation

The products 5 were evaluated for the antifungal activities in vitro against Fusarium graminearum, Botrytis cinerea, Rhizoctoniacerealis and Colletotrichum capsici using a mycelia growth inhibition technique at the concentration of 100 μg/mL [19, 20]. The results are summarized in Table 3. The data indicate that almost all compounds exhibit certain inhibitory activities against four tested plant pathogenic fungi. Compounds 5d and 5f–h show inhibitory rates of 57.1–82.5% against F. graminearum. Compounds 5c–d and 5f–h display inhibitory rates of 58.2–81.8% against B. cinerea. Compounds 5d and 5fg demonstrate inhibitory rates of 71.2–85.7% against R. cerealis. And compounds 5d and 5f–h give inhibitory rates of 61.0–70.6% against C. capsici. It can be seen that the compounds containing substituted phenyl moiety present better bioactivity.

Table 3

Antifungal activities of compounds 5a–h against four plant pathogenic fungi (100 μg/mL, inhibition rate percent).

CompoundsF. graminearumB. cinereaR. cerealisC. capsici
5a20.2±3.52.70±1.306.10±2.0
5b34.1±3.545.3±1.32.9±4.338.2±2.6
5c41.5±2.158.2±2.025.7±1.441.2±0.8
5d75.4±1.380.8±1.971.2±2.762.5±2.3
5e41.9±2.849.3±1.34.8±2.236.8±1.3
5f64.0±2.872.4±0.876.2±0.864.0±1.5
5g82.5±0.881.8±2.085.7±1.461.0±0.8
5h57.1±1.468.9±0.843.3±2.270.6±3.0
TeA10.9±1.718.3±2.813.7±3.114.6±3.0

The values are expressed as means±SD of the replicates; n=3 for all groups. TeA, tenuazonic acid.

Experimental

Melting points were determined on a WRS-1B digital melting-point apparatus and are uncorrected. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were recorded on a Bruker-400 spectrometer in DMSO-d6 solution for compound 5a and CDCl3 solution for compounds 5b–h at room temperature. FT-IR spectra (4000–400 cm-1) were recorded on a Bruker Tensor 27 FT-IR spectrometer in KBr disks. Mass spectra (electron impact) were recorded on a GC/MS-QP2010 spectrometer using a direct injection technique. Elemental analyses were performed on a Vario EL III elemental analyzer. The progress of the reactions was routinely monitored by thin layer chromatography (TLC) on silica gel GF254 and the products were visualized with an ultraviolet lamp (254 and 365 nm). All reagents and starting materials were obtained from commercial suppliers and were used without further purification.

General procedure for the preparation compounds 5a–h

The β-keto amide 2 was prepared according to the reported method [17, 18]. The mixture of 2 (0.2 mol) and sodium methoxide solution (0.2 mol of Na metal and 60 mL of methanol) in benzene (60 mL) was heated under reflux for 4 h. After concentration under reduced pressure, 100 mL water was added to the residue. The aqueous layer was extracted with ethyl acetate to remove the impurities and acidified to pH 2–3 with 20% hydrochloric acid, which furnished an orange oil. This product was purified by crystallization from ethanol below 0°C to give a buff powder of TeA (3). Then compound 3 (10 mmol) and equimolar quantity of hydrazine hydrate were dissolved in absolute ethanol (20 mL), and the solution was heated under reflux with stirring. When TLC analysis (ethyl acetate/light petroleum/acetic acid, V/V, 10:10:1) showed that 3 had been consumed, the reaction was stopped by cooling. The mixture was extracted with ethyl acetate, dried, and concentrated under reduced pressure. The oily residue was crystallized from petroleum/ethyl acetate (V/V, 1:1) below 0oC to provide compound 4a. Compounds 4b–h were synthesized from phenylhydrazine in the presence of trimethylamine (1.2 equiv) at room temperature by using a similar method.

Finally, an ethanol solution (15 mL) of 4 (5 mmol) was treated with 20% hydrochloric acid (1 mmol). The mixture was stirred and heated to reflux until TLC (ethyl acetate/light petroleum, V/V, 1:1) indicated the absence of 4. After cooling, the precipitate was filtrated and washed with a small amount of water and absolute ethanol to give the desired compound 5ah.

(RS)-6-((S)-sec-Butyl)-3-methyl-5,6-dihydropyrrolo[3,4-c]pyrazol-4-(1H)one (5a)

Yellowish powder; yield 70%; mp 192.2–193.7°C; 1H NMR: δ 12.57 (s, 1H, NH), 7.90 (s, 1H, NH), 4.31 (d, J = 2.2 Hz, 1H, CHNH), 4.29 (d, J = 2.6 Hz, 1H, CHNH), 2.31 (s, 3H, CH3), 1.69–1.59 (m, 1H, CH3CH), 1.57–0.94 (m, 2H, CH3CH2), 0.91–0.74 (m, 6H, CH3CH2(CH3)CH); 13C NMR: δ 166.5, 163.0, 135.9, 115.6, 57.3, 38.0, 25.2, 14.6, 12.4, 11.2; IR: 3200, 3088, 2970, 2878, 1701, 1605, 1151, 760 cm-1; MS(EI): m/z 193 (M+, 9), 164 (2), 136 (100), 109 (10), 57 (2). Anal. Calcd for C10H15N3O (193.25): C, 62.15; H, 7.82; N, 21.74. Found: C, 62.23; H, 7.71; N, 21.85.

(RS)-6-((S)-sec-Butyl)-3-methyl-1-phenyl-5,6-dihydropyrrolo[3,4-c]pyrazol-4-(1H)one (5b)

White powder; yield 75%; mp 155.3–156.7°C; 1H NMR: δ 7.60–7.30 (m, 5H, PhH), 6.44 (s, 1H, NH), 6.30 (s, 1H, NH), 4.94 (d, J = 2.7 Hz, 1H, CHNH), 4.83 (d, J = 2.9 Hz, 1H, CHNH), 2.49 (s, 3H, PyCH3), 1.95–1.83 (m, 1H, CH3CH), 1.52–1.25 (m, 1H, CH3CH2 (1H)), 1.01–0.49 (m, 7H, CH3CH2(CH3)CH+CH3CH2 (1H)); 13C NMR: δ 166.6, 155.8, 145.0, 139.1, 129.6, 127.6, 121.1, 120.8, 57.9, 35.7, 27.5, 22.7, 17.1, 12.4, 12.3, 11.8; IR: 3202, 3075, 2966, 2876, 1685, 1598, 1545, 1517, 1142, 763, 674 cm-1; MS(EI): m/z 269 (M+, 17), 212 (100), 184 (3), 116 (5), 77 (19), 57 (5). Anal. Calcd for C16H19N3O (269.34): C, 71.35; H, 7.11; N, 15.60. Found: C, 71.52; H, 7.02; N, 15.37.

(RS)-6-((S)-sec-Butyl)-3-methyl-1-(4-methylphenyl)-5,6-dihydropyrrolo[3,4-c]pyrazol-4-(1H)one (5c)

Colorless crystals; yield 55%; mp 170.5–171.0°C; 1H NMR: δ 7.40 (t, J = 7.9 Hz, 2H, PhH), 7.30 (d, J = 7.7 Hz, 2H, PhH), 6.23 (s, 1H, NH), 6.10 (s, 1H, NH), 4.91 (d, J = 1.8 Hz, 1H, CHNH), 4.80 (d, J = 2.5 Hz, 1H, CHNH), 2.47 (s, 3H, PyCH3), 2.41 (s, 3H, PhCH3), 1.93–1.81 (m, 1H, CH3CH), 1.50–1.26 (m, 1H, CH3CH2 (1H)), 0.99–0.49 (m, 7H, CH3CH2(CH3)CH+CH3CH2 (1H)); 13C NMR: δ 166.7, 155.7, 144.7, 137.6, 136.7, 130.1, 121.1, 120.5, 57.8, 35.5, 27.4, 22.7, 21.1, 17.1, 12.4, 12.3, 11.8; IR: 3191, 3081, 2966, 2875, 1693, 1547, 1523, 1456, 1397, 1142, 807, 745 cm-1; MS(EI): m/z 283 (M+, 25), 246 (2), 226 (100), 130 (3), 91 (13), 77 (2). Anal. Calcd for C17H21N3O (283.37): C, 72.06; H, 7.47; N, 14.83. Found: C, 72.11; H, 7.39; N, 14.92.

(RS)-6-((S)-sec-Butyl)-3-methyl-1-(4-(trifluoromethyl)phenyl)-5,6-dihydropyrrolo[3,4-c]pyrazol-4-(1H)one (5d)

Yellow powder; yield 70%; mp 159.3–160.7°C; 1H NMR: δ 7.76 (d, J = 8.7 Hz, 2H, PhH), 7.68 (d, J = 8.5 Hz, 2H, PhH), 6.10 (s, 1H, NH), 6.00 (s, 1H, NH), 4.99 (d, J = 2.6 Hz, 1H, CHNH), 4.88 (d, J = 2.8 Hz, 1H, CHNH), 2.49 (s, 3H, PyCH3), 1.99–1.89 (m, 1H, CH3CH), 1.54–1.31 (m, 1H, CH3CH2 (1H)), 1.06–0.50 (m, 7H, CH3CH2(CH3)CH+CH3CH2 (1H)); 13C NMR: δ 166.2, 156.0, 145.9, 141.6, 129.3, 126.9, 123.7, 121.8, 120.6, 58.1, 35.6, 27.6, 22.4, 17.4, 12.4, 12.3, 11.8; IR: 3197, 3081, 2964, 2876, 1693, 1615, 1505, 1321, 1112, 1067, 842, 682 cm-1; MS(EI) m/z: 337 (M+, 15), 299 (16), 280 (100), 145 (24), 86 (18), 57 (12). Anal. Calcd for C17H18F3N3O (337.34): C, 60.53; H, 5.38; N, 12.46. Found: C, 60.67; H, 5.52; N, 12.34.

(RS)-6-((S)-sec-Butyl)-1-(4-fluorophenyl)-3-methyl-5,6-dihydropyrrolo[3,4-c]pyrazol-4-(1H)one (5e)

Khaki powder; yield 78%; mp 125.4–127.5°C; 1H NMR: δ 7.51 (dt, J = 9.3, 4.8 Hz, 2H, PhH), 7.68 (t, J = 8.4 Hz, 2H, PhH), 6.33 (s, 1H, NH), 6.21 (s, 1H, NH), 4.90 (d, J = 2.1 Hz, 1H, CHNH), 4.80 (d, J = 2.2 Hz, 1H, CHNH), 2.47 (s, 3H, PyCH3), 1.89–1.77 (m, 1H, CH3CH), 1.52–1.25 (m, 1H, CH3CH2 (1H)), 1.00–0.50 (m, 7H, CH3CH2(CH3)CH+CH3CH2 (1H)); 13C NMR: δ 166.5, 161.6, 155.9, 145.1, 135.3, 123.2, 120.8, 116.6, 57.8, 35.7, 27.4, 22.8, 17.0, 12.4, 12.3, 11.9; IR: 3175, 3080, 2967, 2875, 1697, 1515, 1225, 1145, 1009, 831, 672 cm-1; MS (EI): m/z 287 (M+, 14), 230(100), 134(6), 95(13), 70(5), 57(3). Anal. Calcd for C16H18FN3O (287.33): C, 66.88; H, 6.31; N, 14.62. Found: C, 66.73; H, 6.18; N, 14.49.

(RS)-6-((S)-sec-Butyl)-1-(4-chlorophenyl)-3-methyl-5,6-dihydropyrrolo[3,4-c]pyrazol-4-(1H)one (5f)

Yellow crystals; yield 53%; mp 170.0–171.3°C; 1H NMR: δ 7.50–7.44 (m, 4H, PhH), 6.25 (s, 1H, NH), 6.12 (s, 1H, NH), 4.92 (d, J = 2.0 Hz, 1H, CHNH), 4.81 (d, J = 2.2 Hz, 1H, CHNH), 2.47 (s, 3H, PyCH3), 1.94–1.82 (m, 1H, CH3CH), 1.52–1.28 (m, 1H, CH3CH2 (1H)), 1.02–0.49 (m, 7H, CH3CH2(CH3)CH+CH3CH2 (1H)); 13C NMR: δ 166.4, 155.8, 145.3, 137.6, 133.1, 129.8, 122.2, 121.2, 57.9, 35.6, 27.5, 22.6, 17.2, 12.4, 12.3, 11.9; IR: 3193, 3087, 2967, 2875, 1701, 1598, 1508, 1312, 1145, 1094, 1011, 810, 668 cm-1; MS(EI) m/z: 303 (M+, 24), 274 (2), 246 (100), 111 (10), 75 (6), 57 (4). Anal. Calcd for C16H18ClN3O (303.78): C, 63.26; H, 5.97; N, 13.83. Found: C, 63.29; H, 5.88; N, 13.72.

(RS)-1-(4-Bromophenyl)-6-((S)-sec-butyl)-3-methyl-5,6-dihydropyrrolo[3,4-c]pyrazol-4-(1H)one (5g)

Yellowish powder; yield 72%; mp 165.3–166.0°C; 1H NMR: δ 7.61 (d, J = 8.6 Hz, 2H, PhH), 7.43 (dd, J = 8.8, 4.1 Hz, 2H, PhH), 6.32 (s, 1H, NH), 6.18 (s, 1H, NH), 4.92 (d, J = 2.5 Hz, 1H, CHNH), 4.81 (d, J = 2.7 Hz, 1H, CHNH), 2.47 (s, 3H, PyCH3), 1.94–1.83 (m, 1H, CH3CH), 1.52–1.29 (m, 1H, CH3CH2 (1H)), 1.03–0.49 (m, 7H, CH3CH2(CH3)CH+CH3CH2 (1H)); 13C NMR: δ 166.4, 155.7, 145.4, 138.0, 132.8, 122.4, 121.2, 120.9, 57.9, 35.5, 27.5, 22.6, 17.2, 12.4, 12.3, 11.9; IR: 3186, 3081, 2965, 2874, 1694, 1592, 1504, 1311, 1143, 1072, 807, 664 cm-1; MS (EI): m/z 349 ([M++H], 16), 347 ([M+-H], 17), 292 (100), 183 (18), 155 (12), 76 (15), 57 (14). Anal. Calcd for C16H18BrN3O (348.24): C, 55.18; H, 5.21; N, 12.07. Found: C, 55.32; H, 5.13; N, 12.31.

(RS)-1-(3-Bromophenyl)-6-((S)-sec-butyl)-3-methyl-5,6-dihydropyrrolo[3,4-c]pyrazol-4-(1H)one (5h)

Khaki powder; yield 56%; mp 132.8–134.4°C; 1H NMR: δ 7.77 (s, 1H, ArH), 7.50–7.43 (m, 2H, PhH), 7.35 (t, J = 7.8 Hz, 1H, PhH), 6.46 (s, 1H, NH), 6.34 (s, 1H, NH), 4.98 (d, J = 1.9 Hz, 1H, CHNH), 4.86 (d, J = 2.1 Hz, 1H, CHNH), 2.47 (s, 3H, PyCH3), 1.99–1.87 (m, 1H, CH3CH), 1.55–1.26 (m, 1H, CH3CH2 (1H)), 1.02–0.51 (m, 7H, CH3CH2(CH3)CH+CH3CH2 (1H)); 13C NMR: δ 166.3, 156.0, 145.5, 140.0, 130.9, 130.5, 124.2, 123.3, 121.6, 119.1, 57.9, 35.7, 27.6, 22.8, 17.2, 12.5, 12.4, 11.9; IR: 3186, 3078, 2960, 2872, 1701, 1591, 1498, 1311, 1143, 764, 714, 689 cm-1; MS (EI): m/z 349 ([M++H], 19), 347 ([M+-H], 19), 292 (100), 211 (11), 183 (19), 155 (10), 70 (14). Anal. Calcd for C16H18BrN3O (348.24): C, 55.18; H, 5.21; N, 12.07. Found: C, 55.42; H, 5.08; N, 12.26.

Single-crystal X-ray diffraction analysis of compound 5f

The yellow single crystal of compound 5f grown from ethanol at room temperature, was selected for lattice parameter determination. The intensity data were recorded on a Bruker Smart APEX II CCD diffractometer equipped with graphite monochromatized Mo Kα radiation (λ=0.71073 Å) at 296(2) K. The intensities were corrected for Lorentz and polarization effects, and all data were corrected using the SADABS program [21]. The crystal structure was solved by direct methods using the SHELXS-97 program [22, 23]. All non-hydrogen atoms were refined by full-matrix least-squares technique on F2 with anisotropic thermal parameters. The hydrogen atoms were positioned geometrically and refined using a riding model. Details on crystal data are summarized in Table 1.

The crystallographic data of compound 5f have been deposited as supplementary publication No. CCDC 890343. Copy of this information can be obtained free of charge from the Cambridge Crystallographic Data Centre via fax: +44 1223 336033; e-mail: or http://www.ccdc.cam.ac.uk.


Corresponding author: Chun-Long Yang, Department of Chemistry, College of Science, Nanjing Agricultural University, Nanjing 210095, P.R. China, e-mail:

Acknowledgments

This work was funded by the National Natural Science Foundation of China (No. 31171889) and the Science and Technology Support Program of Jiangsu Province of China (No. BE2012371).

References

[1] Gelin, S.; Chantegrel, B.; Chabannet, M. Synthesis of 4-oxo-1,4-dihydro-6H-furo[3,4-c]pyrazole and 4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole systems from acyl tetronic and tetramic acids. Synthetic Commun. 1982, 12, 431–437.10.1080/00397918208065948Search in Google Scholar

[2] Fariña, F.; Martín, M. V.; Paredes, M. C. Pseudoesters and derivatives. XXV [1]. 1,3-Dipolar cycloaddition of diazomethane to 5-methoxy-3-pyrrolin-2-ones. J. Heterocyclic Chem. 1987, 24, 1269–1274.10.1002/jhet.5570240507Search in Google Scholar

[3] Fahmy, H. M.; Sharaf, M. E.; Aboutabl, M. A. A novel electro-organic synthesis of pyrrolopyrazole derivatives. J. Chem. Soc. Perkin Trans. 21990, 1607–1613.10.1039/p29900001607Search in Google Scholar

[4] Matsuo, K.; Ohta, M.; Ueda, C.; Nakamura, R.; Mawatari, Y.; Tanaka, K. Reaction of phenylhydrazones of 3-acetyl-5, 5-dimethyltetronic and tetramic acids with polyphosphoric acid. Chemistry Express1991, 6, 651–654.Search in Google Scholar

[5] Shibayama, S.; Ikeda, K.; Ri, A.; Miyagi, Y.; Yonekubo, T. Condensed pyrazole derivatives. JP Patent, 57021388 A, 1982.Search in Google Scholar

[6] Komori, T.; Kakimizu, A.; Takaishi, M. Pyrazolines and their use for plant disease control. JP Patent, 2005306805 A, 2005.Search in Google Scholar

[7] Pratik, D.; Washburn, W. N.; Wang, W.; Hernandez, A.; Ahmad, S.; Zhao, G. H. Azolopyrrolone compounds as melanin concentrating hormone receptor-1 antagonists and their preparation. WO Patent, 2010047956 A1, 2010.Search in Google Scholar

[8] Suzuki, S.; Sano, F.; Yuki, H. Studies on antiviral agents. IV. Biological activity of tenuazonic acid derivatives. Chem. Pharm. Bull.1967, 15, 1120–1122.10.1248/cpb.15.1120Search in Google Scholar PubMed

[9] La Croix, E. A. S.; Mhasalkar, S. E.; Mamalisa, P.; Harrington, F. P. Insecticidal activity of some tenuazonic acid analogues. Pestic. Sci. 1975, 6, 491–496.10.1002/ps.2780060508Search in Google Scholar

[10] Janardhanan, K. K.; Husain, A. Phytotoxic activity of tenuazonic acid isolated from Alternaria alternata (Fr.) Keissler causing leaf blight of Datura innoxia Mill. and its effect on host metabolism. Phytopath. Z.1984, 11, 305–311.10.1111/j.1439-0434.1984.tb00774.xSearch in Google Scholar

[11] Gallardo, G. L.; Peña, N. I.; Chacana, P.; Terzolo, H. R.; Cabrera, G. M. L-Tenuazonic acid, a new inhibitor of Paenibacillus Larvae. World. J. Microb. Biotechnol.2004, 20, 609–612.10.1023/B:WIBI.0000043175.23621.8cSearch in Google Scholar

[12] Zhu, Y. Q.; Yao, C. S.; Zou, X. M.; Hu, F. Z.; Liu, B.; Li, Y. H.; Yang, H. Z. The synthesis and herbicidal activity of 1-alkyl-3-(α-hydroxysubstituted benzylidene) pyrrolidine-2,4-diones. Molecules2005, 10, 427–434.10.3390/10020427Search in Google Scholar PubMed PubMed Central

[13] Zhu, X. J.; Huang, L.; Wang, X. F.; Zhu, Z. Y.; Zheng, X. Q.; Qiang, S.; Yang, C. L. Synthesis and biological activities of 3-(1′-alkyloxyiminoethyl)-4-hydroxypyrroline-2- one derivatives. Chin. J. Org. Chem. 2009, 29, 1784–1789.Search in Google Scholar

[14] Zhu, Z. Y.; Shi, Q. M.; Han, B. F.; Wang, X. F.; Qiang, S.; Yang, C. L. Synthesis, characterization and biological activities of novel (E)-3-(1-(alkyloxyamino)ethylidene) -1-alkylpyrrolidine-2,4-dione derivatives. Bull. KoreanChem. Soc. 2010, 31, 2467–2472.10.5012/bkcs.2010.31.9.2467Search in Google Scholar

[15] Royles, B. J. L. Naturally occurring tetramic acids: structure, isolation, and synthesis. Chem. Rev.1995, 95, 1981–2001.10.1021/cr00038a009Search in Google Scholar

[16] Han, B. F.; Shi, Q. M.; Wang, X. F.; Liu, J. B.; Qiang, S.; Yang, C. L. Synthesis and bioactivity of novel 3-(1-hydroxyethylidene)-5-substituted-pyrrolidine-2,4-dione derivatives. Chin. Chem. Lett.2012, 23, 1023–1026.10.1016/j.cclet.2012.07.002Search in Google Scholar

[17] Matsuo, K.; Kimura, M.; Kinuta, T.; Takai, N.; Tanaka, K. Synthesis and antimicrobial activities of 3-acyltetramic acid derivatives. Chem. Pharm. Bull.1984, 32, 4197–4204.10.1248/cpb.32.4197Search in Google Scholar PubMed

[18] Larbig, G.; Schmidt, B. Synthesis of tetramic and tetronic acids as β-secretase inhibitors. J. Comb. Chem.2006, 8, 480–490.10.1021/cc0600021Search in Google Scholar PubMed

[19] Chen, X.; Yang, C. L. Synthesis, controlled release properties, and increased antifungal activities of novel cis- and trans-racemate complexes of propiconazole. J. Agric. Food Chem.2009, 57, 2441–2446.10.1021/jf803415zSearch in Google Scholar PubMed

[20] Zhu, Z. Y.; Wang, X. F.; Meng, F. G.; Li, Q. B.; Zheng, X. Q.; Qiang, S.; Yang, C. L. Synthesis, characterization, and biological activities of novel (Z)-3-((E)-1- (alkyloxyimino)ethyl)-5-arylidene-4-hydroxypyrroline- 2-one derivatives. J. HeterocyclicChem. 2010, 47, 1328–1334.10.1002/jhet.452Search in Google Scholar

[21] Sheldrick, G. M. SADABS, Program for Empirical Absorption Correction, University of Göttingen, Germany, 1996.Search in Google Scholar

[22] Sheldrick, G. M. SHELXS-97, Program for Crystal Structure Solution, Univerity of Göttingen, Germany, 1997.Search in Google Scholar

[23] Sheldrick, G. M. A short history of SHELX. Acta Crystallogr. 2008, A64, 112–122.10.1107/S0108767307043930Search in Google Scholar PubMed

Received: 2015-3-2
Accepted: 2015-8-12
Published Online: 2015-11-28
Published in Print: 2015-12-1

©2015 by De Gruyter

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Articles in the same Issue

  1. Frontmatter
  2. Preliminary Communications
  3. Triphenylphosphine catalyzed domino reaction of dialkyl acetylenedicarboxylate with 3-aryl- 2-benzoylcyclopropane-1,1-dicarbonitrile
  4. Synthesis of colletotrichumine A
  5. Research Articles
  6. Synthesis of the spiroacetal fragments of spirofungins A and B, antibiotics isolated from Streptomyces violaceusniger Tü 4113
  7. Efficient synthesis and fungicidal activities of strobilurin analogues containing benzofuro [3,2-d]-1,2,4-triazolo[1,5-a]pyrimidinone side chains
  8. Synthesis of 2-amino-6,7,8,9-tetrahydro-6-phenethyl-3H-pyrimido[4,5-e][1,4]diazepin-4(5H)-one: a model for a potential pyrimido[4,5-e][1,4]diazepine-based folate anti-tumor agent
  9. Cascade assembling of pyrazolin-5-ones and benzylidenemalononitriles: the facile and efficient approach to medicinally relevant spirocyclopropylpyrazolone scaffold
  10. Synthesis, characterization and bioactivity of novel 5,6-dihydropyrrolo[3,4-c]pyrazol-4- (1H)one derivatives
  11. Molecular modeling and synthesis of new 1,5-diphenylpyrazoles as breast cancer cell growth inhibitors
  12. An efficient synthesis of 11-aryl-10-oxo-7,8,10,11-tetrahydro-1H-[1,2,3]triazolo [4′,5′:3,4]benzo[1,2-b][1,6]naphthyridine derivatives under catalyst-free conditions
  13. Mechanochemical synthesis of 2,2-difluoro-4, 6-bis(β-styryl)-1,3,2-dioxaborines and their use in cyanide ion sensing
  14. Visible-light-mediated radical aryltrichloromethylation of N-arylacrylamides for the synthesis of trichloromethyl-containing oxindoles
  15. A stereolibrary of conformationally restricted amino acids based on pyrrolidinyl/piperidinyloxazole motifs
  16. Synthesis of [1,3]thiazolo[3,2-b][1,2,4]triazol-7-ium and [1,2,4]triazolo[5,1-b][1,3]thiazin-4-ium salts via regioselective electrophilic cyclization of 3-[(2-alken-1-yl)sulfanyl]-4H-1,2,4-triazoles
Downloaded on 23.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/hc-2015-0045/html
Scroll to top button